Skip to main content
OpenTrials
Completed

NCT Number: NCT05062655

Interest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

From a regulatory point of view, medication reconciliation is a necessary process to ensure safe medication management for patients. According to national studies and the international scientific literature, the information received by patients and health professionals at discharge from hospital is insufficient.

Medication reconciliation at discharge reduces medication errors and rehospitalisation, but few studies have been conducted on the impact of a coordinated and reliable care pathway on medication continuity.

The iCoCon study will enable a new healthcare organisation to be set up in order to improve the quality of the patient pathway and the patient's medication management.

This new organisation is part of the policy of continuous improvement of the quality and safety of care

Completed

Looking for future studies?

Notify Me

Key information

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Centre Hospitalier Du Mans

Le Mans, 72000, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • hospitalized patient
  • Patient with a drug treatment with a particular mode of supply
  • Paediatric patient or an adult patient.
  • First inpatient stay over the inclusion period from late 2021 to late 2022

Exclusion criteria

  • Patient under curatorship or guardianship
  • Patient residing abroad
  • No free, informed and written consent obtained

Treatment and study plan

Drug reconciliation

Other

Drug reconciliation information transmission to pharmacist interview with the patient

Primary outcomes

  1. Value of a coordinated and reliable pathway when patients are discharged from the institution via drug reconciliation to ensure the continuity of patients' treatment

    Time frame: 1 month after inclusion

    Value of coordinated pathway is evaluated by number of days of treatment interruption between patient discharge and provision of treatment to the patient

Sponsors and collaborators

Lead sponsor

Centre Hospitalier le Mans

Other

Registry information

Official study title

Nterest of Drug Reconciliation to Ensure the Continuity of the Treatment at Discharge

Acronym: ICOCON

Important dates

Study start
2021
Primary completion
2022
Study completion
2022
First posted
Sep 30, 2021
Registry last updated
Jul 1, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.